Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

FeganScott Announces Investigation into Prenatal Testing Options Revealing Flawed Genetic Results

FeganScott

Today consumer-rights law firm FeganScott announced it has launched a broad-ranging investigation into whether certain national medical laboratories, including Natera (NASDAQ:NTRA), Sequenom (now owned byLabcorp, NYSE: LH), and Quest (NYSE: DGX), provided expectant mothers with lab test results the organizations knew – or should have known – returned unacceptably high percentages of flawed results. In some instances, the flawed results led expectant mothers to believe the children they were carrying had serious genetic abnormalities, according to media reports. “Since we’ve begun our investigation into mothers who were offered prenatal testing and received flawed results, it’s evident this issue is widespread,” said Beth Fegan, founder of FeganScott. “We are examining whether the labs acted appropriately in how they disclosed information regarding the accuracy of the testing, and whether those disclosures were done in a way that allowed parents to make informed decisions regarding the test and test results.” According to media reports, many prenatal tests including Panorama, Prequel, Maternit21 and others are expected to be wrong over half the time and yet they continue to be offered as possible solutions for parents who may be worried about genetic abnormalities. “There a have been other instances in which labs and laboratory testing organizations have delivered flawed results to parents causing great emotional and financial distress. We need to be sure this isn’t happening again,” Fegan added. Individuals who are interested in learning more about this investigation are urged to send their contact information to prenataltesting@feganscott.com. ### About FeganScott FeganScott is a national class action law firm dedicated to helping victims of consumer fraud, sexual abuse, and discrimination. The firm is championed by acclaimed veteran, class action attorneys who have successfully recovered $1 billion for victims nationwide. FeganScott is committed to pursuing successful outcomes with integrity and excellence while holding the responsible parties accountable. Media Only: Mark Firmani feganscottpr@firmani.com 206.466.2700 About FeganScott FeganScott is a national class action law firm dedicated to helping victims of civil rights violations, sexual abuse, sexual harassment, and consumer fraud. The firm is championed by acclaimed veteran, class action attorneys who have successfully recovered $1 billion for victims nationwide. FeganScott is committed to pursuing successful outcomes with integrity and excellence while holding the responsible parties accountable. Contact Details Mark Firmani +1 206-466-2700 feganscottpr@firmani.com Company Website https://feganscott.com

January 17, 2022 09:07 AM Pacific Standard Time

Elsevier appoints Laura Hassink as Managing Director, STM Journals

Elsevier

Elsevier, a global leader in research publishing and information analytics, is pleased to announce the appointment of Laura Hassink as the new Managing Director for STM Journals, succeeding Philippe Terheggen, who has retired at the end of 2021 after a distinguished 30-year career at Elsevier. Laura will be responsible for Elsevier's portfolio of 2,650 journals managed by more than 24,000 editors, who collectively publish more than 560,000 research articles a year. Laura is currently Elsevier’s Senior Vice President of Publishing Transformation, overseeing all aspects of operational support for its journals, improving, and innovating the publication experience for authors, peer reviewers and editors. Laura has also been instrumental in accelerating Elsevier’s substantial progress in open access publishing, with the company now offering more than 600 gold open access journals, as well as offering open access publishing options across all its portfolios. Before her current role, Laura served as SVP Product Management for ScienceDirect and Journal Branded Solutions, responsible for defining the strategy and product roadmap to improve customers’ reading experience and visibility of the journals Elsevier publishes. During her 24 years with Elsevier, she also served as SVP Physical Sciences in STM Journals and held positions in Strategy, Business Development and Journal Services. Since 2015, Laura has been active as a board member of the Dutch Publishers Association, Mediafederatie and Chair of the Media Voor Vak en Wetenschap (MVW), and serves as Chair of the Open Science Forum. She holds a Master’s degree in Economics from Vrije Universiteit, and a Bachelor's degree in Business Administration from Nyenrode Business Universiteit. Elsevier’s CEO, Kumsal Bayazit, commented on the appointment: “Laura has a genuine passion for understanding the needs of the research communities we serve and maintaining the highest quality and integrity standards in scholarly communications. She is also the perfect leader to continue to build on Elsevier’s 140-year heritage as the global leader in scientific publishing, helping to ensure quality research contributes to societal progress.” About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Media contact Andrew Davis Elsevier Communications +44 7393 242 466 andrew.davis@elsevier.com Contact Details Elsevier Communications Andrew Davis +44 7393 242466 andrew.davis@elsevier.com Company Website https://www.elsevier.com/

January 17, 2022 05:16 AM Eastern Standard Time

Image

G Medical Innovations (NASDAQ: GMVD) is forecasting incremental Q1 revenues at around $30 MM, based on revenue generated from G Medical Tests and Services’ physical storefront testing locations

G Medical Innovations Holdings

Dr. Yacov Geva, President and CEO of G Medical Innovations, and Michael McDade, CEO of McDade Products, LLC, announced today that they acquired an undisclosed number of shares of G Medical Innovations (NASDAQ: GMVD). The CEO of McDade Products, LLC cited high confidence levels for sales of the co-branded LiveNow COVID-19 PCR Test Collection Kits announced this week and the forecasting of $30MM in revenues generated from the successful storefront COVID-19 testing locations operated by the company’s G Medical Tests and Services division. G Medical Tests and Services currently operates storefront testing locations in California. During the next few months, the company expects to expand its network of storefront testing locations in California and other U.S. regions to be announced at a later date. Pittsburgh-based McDade Products, LLC and G Medical Tests and Services have partnered to make millions of FDA EUA-approved COVID-19 PCR collection test kits available for retailers to sell by the end of January, in response to a national shortage of COVID-19 test options. The LiveNow COVID-19 PCR Test Collection Kits provide 24–48-hour certified lab results and retail for $9.99. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. “With the U.S. government’s shift to emphasize COVID-19 testing to combat this virus, I’ve acquired stock with G Medical on the open market because I strongly believe in the future of the company. As a trusted and proven mobile health and e-health company, G Medical is now making SARS-CoV2 certified lab testing even more accessible and convenient for consumers,” said Michael McDade, CEO of McDade Products, LLC. McDade Products is a division of McDade Group, a privately held specialty sales, marketing, and distribution company serving the U.S. retail industry. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders and anticipated gross profits. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 14, 2022 07:00 AM Eastern Standard Time

Altais Launches New Multi-Specialty Independent Medical Practice in Riverside, CA

Altais

Healthcare services company Altais today announced the launch of a state-of-the-art multi-specialty medical group in Riverside, California. The new Altais Medical Group Riverside will provide a wide range of specialties from primary care and obstetrics and gynecology to interventional cardiology for community members in Riverside County beginning in February 2022. The nearly 11,000-square-foot facility is located at 4646 Brockton Ave, Riverside CA 92506. Leading up to the official opening of Altais Medical Group Riverside’s offices, prospective patients and others can visit www.amgriverside.com for more information. Visitors can also sign up online to receive important news and updates about the group via email or text, including when they can register as a new patient and schedule an appointment with a physician. The new Altais Medical Group Riverside is founded on a patient-centric model of care and provides comprehensive primary and specialty care. Services provided include everything from routine check-ups to specialized cardiac, obstetric, gynecologic, urologic and gastroenterological care. “The doctors and our healthcare teams at Altais Medical Group Riverside are all seasoned professionals with a deep commitment to serving the Riverside community,” said Rodolfo Saenz, M.D., an obstetrician / gynecologist at the new Riverside office. “Altais Medical Group Riverside patients will benefit from having multiple specialists under one roof. At the same time, we are fully committed to collaborating closely with the referral and hospital network already in place here in the Inland Empire. We are confident that new patients will appreciate the quality of care and patient-centric approach we provide.” Altais is a healthcare services company creating business models and integrated, scalable technology solutions that enhance the patient experience, improve health outcomes, reduce cost, and drive professional gratification among physicians. Altais invests directly in physician practices, clinics and related business models. In 2020, Brown & Toland Physicians, a network of more than 2,700 independent physicians in the San Francisco Bay Area, joined the Altais family of companies. Los Angeles’ Family Care Specialists, one of the largest community-based and Latinx-led private medical groups in California, joined Altais in December 2021. Altais also has two independent primary care clinics serving essential civic employees and educators in the Monterey-Salinas market. Recent studies show the greater Riverside community may have a deficit of up to 1,000 physicians to serve a growing Riverside County population of well over 2 million residents. Altais Medical Group Riverside aims to address that shortage by providing a new model of independent practice that, in time, can serve to attract more healthcare professionals to the region. “Altais is proud to launch this new medical practice group in Riverside County,” said Jeff Bailet, M.D., president and chief executive officer for Altais. “Over the past decade, the healthcare field generally and the Riverside community in particular – has experienced unprecedented levels of physician burnout and early retirements. Independent physicians have been overwhelmed by the administrative demands of maintaining their practices. Altais’ mission is to focus on reversing that trend and provide independent physicians with the business practices and technologies that help them not just endure but thrive during this difficult period and beyond. We are excited to bring that vision of medical practice vibrancy to reality in Riverside.” * * * ABOUT ALTAIS Altais is a healthcare services company that helps physicians and the clinical community maximize the health and well-being of their patients in an affordable and sustainable way. Altais has two divisions. Altais Clinical Services offers a range of affiliation and employment models for physicians and high-quality, affordable care for patients. Altais Health offers a broad platform of clinical support tools and technology, along with high-touch support. Ultimately, Altais seeks to enhance the vibrancy of physician practice and strengthen the heart of medicine – physicians connecting with patients and providing personalized, high-quality care. For more information about Altais, please visit www.altais.com. # # # Media, please note: For interview and image requests, please contact Robin Carr at (415) 971-3991 or altais@landispr.com. Contact Details Landis Communications Inc. Robin Carr +1 415-971-3991 altais@landispr.com Company Website https://altais.com/

January 12, 2022 06:00 AM Pacific Standard Time

Image

McDade Products, LLC and G Medical Tests Secure Additional Purchase Order for $6.5 Million, Reflecting $3.5 Million Gross Margin, to be Delivered in Q1

G Medical Innovations Holdings

PITTSBURGH, PA – McDade Products, LLC and G Medical Tests and Services, a division of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), today announced an additional $6.5 million purchase order for two million COVID-19 PCR collection test kits. G Medical will be selling these units wholesale for $3.25 each, reflecting a gross profit of approximately $3.5 million. Additionally, G Medical expects to be paid an average of $85.00 per test through each patient’s insurance. “McDade is pleased to be expanding upon its existing purchase order so quickly and expects to be ordering a further seven million test kits in the next thirty days.” These orders seem to come at a pertinent moment with the Biden Administration recently requiring that private insurers pay for a minimum of eight COVID 19 test kits per person per month starting January 15 th. G Medical Tests and Services is delighted to provide McDade with current and future purchase orders. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders and anticipated gross profits. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 12, 2022 07:00 AM Eastern Standard Time

Most Lives Saved by Organ Transplant in a Single Year

United Network for Organ Sharing

In 2021, a historic 41,354 organ transplants were performed in the U.S., an increase of 5.9 percent over 2020 and the first time the annual total exceeded 40,000, according to preliminary data from United Network for Organ Sharing (UNOS), the engine that powers the nation’s organ donation and transplantation system. The three organs most commonly transplanted also set annual records. There were 24,669 kidney transplants, 9,236 liver transplants and 3,817 heart transplants in 2021. Liver transplant totals have set annual records for the past nine years, and heart transplants have set a new record every year for the past decade. “We are gratified that transplantation continues to increase substantially and meet the needs of many more people with organ failure, despite ongoing challenges to healthcare relating to the COVID-19 pandemic,” said Matthew Cooper, M.D., FACS, president of the UNOS Board of Directors. “This speaks to the dedication and collaboration of donor hospitals, organ procurement organizations and transplant hospitals striving to ensure every opportunity to give the gift of life is pursued and celebrated." Thanks to the generosity of selfless donors and their courageous families, deceased organ donations continued its 11-year record trend. Increases in donation occurred in many areas throughout the nation. Of 57 organ procurement organizations (OPOs), 49 experienced an increase in donation over their 2020 total. Forty-five OPOs set all-time records for donors recovered in a single year. “As always, we are indebted to the many thousands of people who make these transplants possible through the selfless gift of organ donation,” Cooper said. “And we are reminded daily of our need to help the tens of thousands of men, women and children continuing to await a lifesaving transplant.” Learn more about organ donation and transplantation and how to register to be a donor at www.unos.org. Dr. Cooper is a transplant surgeon and the director of kidney and pancreas transplantation at MedStar Georgetown Transplant Institute at MedStar Georgetown University Hospital. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN ) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

January 11, 2022 11:20 AM Eastern Standard Time

Image

GLOBAL INDUSTRY LEADER NEAL GUTTERSON JOINS GROUNDWORK BIOAG’S ADVISORY BOARD

Groundwork BioAg

Groundwork BioAg® expanded its advisory board with the addition of Neal Gutterson, PhD, Chief Technology Officer and Partner at Radicle Growth and recently retired Chief Technology Officer at Corteva. Recognized as a world-class scientist in agricultural biotechnology, Gutterson brings in-depth experience advancing innovation and biological platforms to deliver greater value to farmers around the world. “Innovation in biologicals and regenerative practices are helping to restore soil health and carbon permanence while ensuring plant nutrition, with less phosphorus fertilizer. But more must be done to accelerate mainstream adoption of these solutions and engage everyone across the food supply chain—from farmers to consumers—to restore overall sustainability. At Groundwork BioAg, this is our mission. We look forward to working with Neal as our advisor and are delighted to tap into his unique experiences,” said Dr. Yossi Kofman, Co-Founder and Chief Executive Officer at Groundwork BioAg. Prior to his role at Corteva, Gutterson led Mendel Biotechnology as CEO, where he expanded the company’s plant gene network platform to improve productivity, resource use efficiency and stress tolerance of key agricultural crops. Today, Gutterson serves as CTO and Partner at Radicle Growth and on the System Board of CGIAR. In the past, he has served on the Board of Directors for the International Maize and Wheat Improvement Center (CIMMYT) as well as several organizations focused on technology advancements that improve the overall sustainability of crop production. “Tremendous progress has been made to expand biological innovation in the last decade, however, to combat climate change and restore the overall health of our food supply, we must look deeper into our soils,” said Gutterson. “I’m delighted to join Groundwork BioAg’s advisory board to help the company achieve the full potential of its proven science, while tackling existential challenges like permanent soil carbon sequestration and chronic drought.” In 2021, Groundwork BioAg accelerated mass production of its highly concentrated, cost-effective mycorrhizal inoculants and unlocked its technology platform to quickly scale product development. The company has consistently delivered year-over-year sales growth and expanded its global presence. In addition to increasing yield, Groundwork BioAg’s mycorrhizal inoculants improve sustainability by reducing dependency on phosphorus fertilizer and improving carbon sequestration in soil. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

January 11, 2022 08:00 AM Central Standard Time

Image

Biomedical AI entrepreneur Prof. Amir Geva appointed CSO of SleepX

Appyea

World renowned machine learning and bio-feedback expert joins company to execute and lead the development of DreamIT – the company’s patented solution integrating its proprietary AI technology in a wearable data driven wristband to treat sleep apnea and snoring. SleepX, a subsidiary of AppYea (OTC: APYP) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announced today the appointment of Biomedical AI entrepreneur Prof. Amir Geva, as its chief science officer. Prof. Geva is a world-renowned expert in the field of machine learning, with over 25 years of business leadership experience as the founder and R&D teams leader of biomedical AI companies Elminda, InnerEye and WideMed. He brings over 40 years of deep AI research, serving today as the Head of the Biomedical Signal Processing and Machine Learning Lab and as Professor at the Electrical and Computers Engineering Department at Ben Gurion University of the Negev in Israel. As of today, Prof. Geva had published 62 scientific articles, and he is Senior Member at the Biomedical Engineering and Computers of the IEEE. In the past he had served also as consultant to the Israeli Air Force and Elbit on bioelectrical signal processing. He is DSc in Biomedical Engineering from the Technion Israel Institute of Technology, and formerly a Major at the Israeli Navy. "SleepX’ is the right solution many had been waiting for", Prof. Amir Geva commented. "The company has introduced a revolutionary combination of sensor technology, data analysis and machine learning to take on the challenge sleep-training for adults and improving people’s sleep and general wellbeing. I look forward to working with the team to complete the development of the company’s product and realize its market potential." SleepX is an Israeli research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. The company currently focuses its activities on the development and commercialization of its flagship product DreamIT. "We are honored to have a world expert in bio-feedback and AI such as Prof. Geva joining us to lead the development of our product’s brain analysis capabilities and advance the execution of our go-to-market strategy to realize the company’s business plan", said Boris (Bary) Molchadsky, President and CEO of SleepX, and Chairman at AppYea. Contact Details AppYea Inc. Asaf Porat info@appyea.com Company Website http://www.appyea.com

January 11, 2022 08:24 AM Eastern Standard Time

Image

Asset Preservation Strategies Inc. Raises Impactful Funding for Rady Children’s Hospital

Asset Preservation Strategies

Founder and Chairman of Asset Preservation Strategies, John Jenkins, has served as a member of the Estates and Trusts Committee for Rady Children’s Hospital Foundation for over 15 years. His journey provided him with a front row seat to the positive effects the hospital and its services have on every aspect of child healthcare – not just in San Diego, but throughout Southern California, nationally, and internationally. Parents bring their children to Rady Children’s Hospital from all over the world for its excellence, and child healthcare specialties that can be lifesaving. Inspiring his team to support Rady Children’s hospital, John Jenkins, alongside CEO and Senior Financial Adviser Greg Banner, and Monica Szakos, President and Senior Financial Adviser, Asset Preservation Strategies united to create this impactful fundraiser. The campaign effectively raised money for the funding of five critical institutes created to expand specialized pediatric care which include: Rady Children's Institute for Genomic Medicine, Heart Institute, Autism Discovery Institute, Mental and Behavioral Health Institute, and The Peckham Center for the Treatment of Pediatric Cancer. One amazing new development is that the Genomic Institute can run an entire DNA analysis in 19 hours. They have already solved numerous, critical, newborn issues by discovering the dysfunctional gene and prescribing treatment within the first 24 hours of life – simply astounding! “Our firm was built on the belief that managing wealth wisely can make a difference in the lives of others. We believe in investing in the community and in turn, the future.” –John Jenkins, Chairman and Senior Financial Adviser, Asset Preservation Strategies About Asset Preservation Strategies: Asset Preservation Strategies offers collaborative wealth management for affluent individuals and families. For over 30 years, their team of experienced financial advisors has specialized in working closely with affluent individuals and families to create customized client portfolios, incorporating sophisticated tax planning and advanced estate planning strategies, in careful collaboration with each professional that plays a part in handling the client’s finances. As fiduciaries, the team at APS is not only required by law to keep clients’ interests first, but their passion and primary goal is to advance responsible stewardship of assets and achieve the best possible outcome for each client. NO OFFER OR SOLICITATION: The contents of this press release: (i) do not constitute an offer of securities or a solicitation of an offer to buy securities, and (ii) may not be relied upon in making an investment decision related to any investment offering. Asset Preservation Strategies, Inc is a DBA of Axxcess Wealth Management, LLC, an SEC Registered Investment Advisor. Investment Advisory Services offered through Axxcess Wealth Management, LLC. Securities offered through Arete Wealth Management, LLC Member FINRA, SIPC, NFA Asset Preservation Strategies, Inc., Arete Wealth Management, LLC nor Axxcess Wealth Management, LLC are affiliated. Axxcess and Arete do not warrant the accuracy or completeness of the information contained herein. Opinions are our current opinions and are subject to change without notice. Prices, quotes, rates are subject to change without notice. Generally, investments are NOT FDIC INSURED, NOT BANK GUARANTEED and MAY LOSE VALUE. Brokerage services are offered through Arete Wealth Management, LLC Member FINRA, SIPC, NFA. Information pertaining to Arete Wealth Management, LLC and its registered persons are available through the FINRA's Broker Check System or by calling the FINRA's Broker Check Hotline at (800) 289-9999. Learn More: Asset-Preservation.com Contact Details Sterling Public Relations Paula Steurer +1 949-200-6566 concierge@sterlingpublicrelationsoc.com Company Website https://asset-preservation.com/

January 10, 2022 01:00 PM Pacific Standard Time

1 ... 241 242 243 244 245 ... 305